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Our meta-analysis of 5-year
data from published ran-
domized trials of partial-
breast irradiation (alone or
within a risk-adapted
approach) versus whole-
breast irradiation for invasive
breast cancer treated with
lumpectomy found no dif-
ference in breast cancer
mortality (nZ4489; differ-
ence, 0.000% [95% confi-
dence interval (CI), 0.7 to
þ0.7]; PZ.999). Partial-
breast irradiation was better
than whole-breast irradiation
for nonebreast -cancer mor-
tality (nZ4231; difference,
1.1% [95% CI, 2.1% to
0.2%]; PZ.023) and total
mortality (difference, 1.3%
[95% CI, 2.5% to 0.0%];
PZ.05), leading to a 25%
relative risk reduction.Purpose: With earlier detection and more effective treatment, mortality from breast
cancer continues to fall and it has become increasingly important to reduce the toxicity
of treatments. Partial-breast radiation therapy, which focuses radiation to the tumor
bed, may achieve this aim. We analyzed mortality differences in randomized trials
of partial-breast irradiation (PBI).
Methods and Materials: We included data from published randomized trials of PBI
(alone or as part of a risk-adapted approach) versus whole-breast irradiation (WBI)
for invasive breast cancer suitable for breast-conserving therapy. We identified trials
using PubMed and Google searches with the terms “partial breast irradiation” OR
“intraoperative radiotherapy” OR “IMRT” OR (“accelerated” AND “radiation”)
AND “randomised/randomized,” as well as through discussion with colleagues in
the field. We calculated the proportion of patients who had events in each
randomized arm at 5 years’ follow-up and created a forest plot using Stata, version
14.1.
Results: We identified 9 randomized trials of PBI versus WBI in invasive breast can-
cer; 5-year outcomes were available for nonebreast cancer mortality in 5 trials
(nZ4489) and for breast cancer mortality in 4 trials (nZ4231). The overall mortality
was 4.9%. There was no detectable heterogeneity between the trials for any of the
outcomes. There was no difference in the proportion of patients dying of breast can-
cer (difference, 0.000% [95% confidence interval (CI), 0.7 to þ0.7]; PZ.999).
Nonebreast cancer mortality with PBI was lower than with WBI (difference, 1.1%
[95% CI, 2.1% to 0.2%]; PZ.023). Total mortality with PBI was also lower than
with WBI (difference, 1.3% [95% CI, 2.5% to 0.0%]; PZ.05).
Conclusions: Use of PBI instead of WBI in selected patients results in a lower 5-year
nonebreast cancer and overall mortality, amounting to a 25% reduction in relative
terms. This information should be included when breast-conserving therapy is pro-
posed to a patient.  2016 The Author(s). Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
Concern over toxicity of radiation therapy after breast-
conserving surgery is particularly relevant today as
earlier diagnosis and more effective treatments have
vastly improved the prognosis for women with early
breast cancer. Many such women now die as the result of
a cause other than the breast cancer. Furthermore, up to
50% of screen-detected cancers are overdiagnosed and
would have not posed any threat to the women in the first
place (1). It is therefore important to ensure that our
treatments do not increase the risk of nonebreast cancer
deaths.
Several of the randomized clinical trials of partial-
breast irradiation (PBI) appear to have found small dif-
ferences in nonebreast cancer mortality favoring PBI (2-
8). Even though these trials used diverse methods to
irradiate the breast (interstitial wires, intraoperative radi-
ation therapy, external beam radiation therapy), they all
aimed to only irradiate the immediate vicinity of the tumor
bed to achieve good breast cancer control while sparing
other organs.
We performed a meta-analysis of PBI versus
wholebreast irradiation (WBI) in women undergoingbreast-conserving therapy for the outcomes of breast cancer
mortality, nonebreast cancer mortality, and total mortality.
Methods and Materials
For this meta-analysis, we considered all published ran-
domized controlled trials comparing PBI versus WBI for
breast cancer treated with breastconserving therapy. We
identified trials using PubMed and Google searches with
the terms “partial breast irradiation” OR “intraoperative
radiotherapy” OR “IMRT” OR (“accelerated” AND “radi-
ation”) AND “randomised/randomized,” as well as through
discussion with colleagues in the field. Searches were car-
ried out during November 2015.
It remains unclear what length of follow-up is required
to obtain robust data on nonebreast cancer mortality.
Historical studies have suggested that one needs to wait 10
or 15 years for such differences to arise; however, in more
recent trials differences seem to appear much earlier. We
planned to include all randomized trials that reported the
number of breast cancer and nonebreast cancer deaths at
5 years. For the TARGIT-A trial (risk adapted targeted
intraoperative radiation therapy [TARGIT IORT] vs whole-
breast external beam radiation therapy [EBRT]), we used
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follow-up of 5 years.
Data extraction
Data were independently extracted by 2 authors (J.S.V. and
M. Bulsara).
Statistical analysis
We used the absolute number of events and calculated the
proportion of patients who had events in each randomized
arm. We calculated the difference in this proportion and its
confidence interval (CI). A forest plot was created by
standard meta-analysis methods using weighted values.
Statistical analysis was performed with Stata, version 14.1
(command metan; StataCorp, College Station, TX). For
completion, we used both the random-effects model and the
fixed-effects model to analyze the data.
Publication bias
We have considered all trials comparing PBI with WBI that
have been performed to date. We considered only the
published results. Publication bias is unlikely because the
main outcome in this article is mortality, which is a sec-
ondary outcome in all these trials. The decision to publish
or to withhold publication would not have been influenced
by this outcome.
Assessment of study quality
As there are only a handful of studies, we included all
studies in which data were available. Only the TARGIT-A
trial report (3) has mentioned that the cause of death was
ascertained by a senior clinician who was blinded to the
randomization allocation. However, all other studies have
reported the cause of death, and we have trusted the pub-
lished report and used the raw numbers that were reported.
A patient was involved in the discussions leading to the
development of the research question and outcome mea-
sures, and her priorities, experience, and preferences
influenced it. The patient was not involved in the actual
conduct of this meta-analysis but has seen and commented
on the early drafts and final version.
Results
We identified 9 published randomized trials (3, 5-12), of
which 8 had reported outcome data. The Canadian RAPID
trial (Randomized Trial of Accelerated Partial Breast Irra-
diation) (12) outcomes have not been reported yet. Three
trials [Christie Hospital (nZ708) (9), Leeds (nZ174) (10),
and Barcelona (nZ102) (11)] have not reported numbers of
breast cancer and nonebreast cancer deaths and could notbe included. The National Surgical Adjuvant Breast and
Bowel Project-B 39 (NSABP-B-39) trial is still recruiting,
and the Intensity Modulated Partial Organ RadioTherapy-
Low (IMPORT-LOW) trial results are yet to be published.
The Budapest trial authors report only the first event (5)
and have not reported apportioning of their 9 breast cancer
deaths between the two randomized arms. Because the 5-
year estimate of breast cancer survival favored PBI
(98.3% [95% CI, 96.0%-100%] for PBI vs 96.0% [95% CI,
92.4%-99.6%] for WBI), this trial’s exclusion would work
against favoring PBI for breast cancer mortality. We only
included the nonebreast cancer deaths from the afore-
mentioned trial in the meta-analysis. Thus 5 trials
(nZ4489) were included for the analysis of nonebreast
cancer mortality (3, 5-8) and 4 trials for the analysis of
breast cancer and overall mortality (nZ4231) (3, 6-8). In
addition, in this trial, overall survival with PBI (94.6%) was
better than with WBI (91.8%). Again, we could not include
these data because the exact numbers of events for overall
survival and breast cancer survival were not available. If we
could have included these values, it would have strength-
ened the results rather than diluting them.
The forest plot is shown in Figure 1. There was no
detectable heterogeneity between the trials for breast cancer
mortality (PZ.360), nonebreast cancer mortality
(PZ.318), or total mortality (PZ.346).
In both the fixed-effects and random-effects models,
there was no difference in breast cancer mortality with PBI
and WBI: the difference in the proportion of patients dying
of breast cancer was 0.000% (95% CI, 0.7% to þ0.7%;
PZ.999) for the random-effects model and 0.3% (95% CI,
0.5% to þ1.2%; PZ.484) for the fixed-effects model.
Nonebreast cancer mortality with PBI was significantly
lower than with WBI (difference of 1.1% [95% CI, 2.1%
to 0.2%], PZ.023, by random-effects model and 1.3%
[95% CI, 2.3% to 0.3%], PZ.011, by fixed-effects
model). Finally, total mortality was also lower with PBI
compared with WBI (difference of 1.3% [95% CI, 2.5%
to 0.0%], PZ.05, by random-effects model and 1.0% [95%
CI, 2.3% to 0.3%], PZ.13, by fixed-effects model).Discussion
In this meta-analysis we found that in women with breast
cancer, there is a small but definite reduction in mortality
when PBI is given instead of WBI. On the basis of the 2
statistical models, the absolute difference in nonebreast
cancer mortality is 1.1% to 1.3% and is statistically signif-
icant (PZ.023 or PZ.011). Because there was no difference
in breast cancer mortality, the reduction in nonebreast
cancer mortality appears to translate into a reduction in
overall mortality. The absolute difference in overall mor-
tality is likely to be between 1.0% and 1.3%. The low P
values of PZ.15 or PZ.05 indicate the improbability of
observing this difference if there was no real difference
between PBI and WBI. Given that the total mortality was
Non-BC Deaths
Budapest
ELIOT
GEC-ESTRO
IMRT
TARGIT-A
BC Deaths
ELIOT
GEC-ESTRO
IMRT
TARGIT-A
Total Deaths
ELIOT
GEC-ESTRO
IMRT
TARGIT-A
Trial name
5/130
11/654
28/551
4/260
29/609
77/2204
20/654
4/551
3/260
13/609
40/2074
31/654
32/551
7/260
42/609
112/2074
WBI
Events,
-0.007 (-0.052, 0.038)
0.000 (-0.014, 0.014)
-0.014 (-0.038, 0.009)
-0.015 (-0.032, 0.001)
-0.025 (-0.045, -0.004)
-0.013 (-0.023, -0.003)
0.005 (-0.015, 0.024)
-0.001 (-0.010, 0.008)
-0.008 (-0.023, 0.007)
0.010 (-0.008, 0.028)
0.003 (-0.005, 0.012)
0.005 (-0.019, 0.028)
-0.015 (-0.041, 0.010)
-0.023 (-0.044, -0.002)
-0.015 (-0.042, 0.012)
-0.010 (-0.023, 0.003)
4/128
11/651
23/633
0/260
14/613
52/2285
23/651
4/633
1/260
19/613
47/2157
34/651
27/633
1/260
33/613
95/2157
PBI
Events,
Favors PBI  Favors WBI 
-.05 0 .05
Non-BC Deaths
Budapest
ELIOT
GEC-ESTRO
IMRT
TARGIT-A
Subtotal
BC Deaths
ELIOT
GEC-ESTRO
IMRT
TARGIT-A
Subtotal
Total Deaths
ELIOT
GEC-ESTRO
IMRT
TARGIT-A
Subtotal
Trial name
5/130
11/654
28/551
4/260
29/609
77/2204
20/654
4/551
3/260
13/609
40/2074
31/654
32/551
7/260
42/609
112/2074
WBI
Events,
-0.007 (-0.052, 0.038)
0.000 (-0.014, 0.014)
-0.014 (-0.038, 0.009)
-0.015 (-0.032, 0.001)
-0.025 (-0.045, -0.004)
-0.011 (-0.021, -0.002)
0.005 (-0.015, 0.024)
-0.001 (-0.010, 0.008)
-0.008 (-0.023, 0.007)
0.010 (-0.008, 0.028)
-0.000 (-0.007, 0.007)
0.005 (-0.019, 0.028)
-0.015 (-0.041, 0.010)
-0.023 (-0.044, -0.002)
-0.015 (-0.042, 0.012)
-0.013 (-0.025, -0.000)
4/128
11/651
23/633
0/260
14/613
52/2285
23/651
4/633
1/260
19/613
47/2157
34/651
27/633
1/260
33/613
95/2157
PBI
Events,
Favors PBI  Favors WBI 
-.05 0 .05
Difference in the
proportion of patients
with an event (95%CI)
Difference in the
proportion of patients
with an event (95%CI)
Fixed-effects model
Random-effects model
Total P=.011
Total P=.484
Total P=.131
Total P=.023
Total P=.999
Total P=.05
Vaidya et al. International Journal of Radiation Oncology  Biology  Physics262
Volume 96  Number 2  2016 Reduced mortality with partial breast irradiation 263only 4.9% (207 of 4231), in relative terms, this is a 25%
reduced mortality with PBI; thus it would also be clinically
significant. Given the high incidence of breast cancer, it
could also translate into large numbers at a population scale.
For example, if 25% of patients who receive the diagnosis in
the United Kingdom every year are eligible for PBI (10,000
of 40,000), it would result in 130 fewer deaths.
There are 2 popular statistical models for meta-analysis,
the fixed-effects model and the random-effects model, and
it is important to recognize the differences between them
for careful interpretation of the results (13). Under the
fixed-effects model, it is assumed that the true effect size
for all studies is identical and the only reason that the effect
size varies between studies is the within-study estimation
error, and weights are assigned accordingly (based solely
on the within-study variances); therefore, the smaller
studies are largely ignored. By contrast, under the random-
effects model, the goal is not to estimate one true effect but
to estimate the mean of a distribution of effects. Because
each study provides information about a different effect
size, one needs to be sure that all these effect sizes are
represented in the summary estimate. This means that one
cannot discount a small study by giving it a very small
weight (the way we would in a fixed-effects analysis). The
estimate provided by that study may be imprecise, but it is
information about an effect that no other study has esti-
mated. By the same logic, we cannot give too much weight
to a very large study (the way we might in a fixed-effects
analysis). Our goal is to estimate the mean effect in a
range of studies, and we do not want that overall estimate to
be overly influenced by any one of them (13).
Therefore, the results from the random-effects model are
more likely to be an accurate reflection of reality for the
following reasons. First, the data come from a series of
studies performed in different countries, and it would be
unlikely that all the studies were functionally equivalent.
The subjects and particularly the interventions varied, with
radically different methods of delivering PBI, with differing
dose rates beam energy, duration of treatment, and area
covered (single-dose photons at 50 kV for 20-30 minutes
for TARGIT IORT, single-dose electrons at 6 MeV for 4-
6 minutes for electron intraoperative radiation therapy
[ELIOT], multiple fractions using high energy for intensity
modulated radiation therapy (IMRT), and radioactive wires
for GEC-ESTRO [Groupe Europe´en de Curiethe´rapie of
European Society for Radiotherapy and Oncology]). Thus
these studies differed in ways that would have affected the
results, and therefore, we should not assume a common
effect size.Fig. 1. Forest plots representing meta-analysis of difference
whole-breast irradiation (WBI) with fixed-effects model and rand
(Non-BC) mortality were the Budapest trial (5), TARGIT-A (3),
follow-up of all these trials was 5 to 6 years. Data from only the
follow-up was 5 years, were included. The Budapest trial was n
total deaths because these figures were not available. As discusseAs such, in these cases the random-effects model is
more easily justified than the fixed-effects model. In addi-
tion, the goal of this analysis is usually to generalize to a
range of populations. Therefore, if one did make the
argument that all the studies used an identical, narrowly
defined population, then it would not be possible to
extrapolate from this population to others, and the utility of
the analysis (based on a fixed-effects model) would be
limited (13). In any case, in this particular meta-analysis,
the specific results from the 2 models are not materially
different.
About 15% of patients in the TARGIT arm of the
TARGIT-A trial received EBRT as part of the risk-adapted
approach. If receiving PBI instead of WBI indeed leads to
reducing mortality, then including these patients should
bias toward the null hypothesis and excluding them should
strengthen the association between treatment with PBI or
TARGIT IORT and improved overall survival. When we
performed such a “sanity check” analysis, we found that,
indeed, the risk difference in overall mortality increased
from 1.5% to 1.75%. This result, albeit from a non-
randomized comparison, could be considered akin to a
dose-response relationship and reassured us that our find-
ings were internally consistent.
The results of these meta-analyses demonstrate the
hitherto underrecognized risks of whole-breast external
beam radiation therapy. One might argue that radiation
therapy techniques have improved in recent years, although
these modern trials were conducted largely when cardiac
sparing was being actively considered (14). However, we
cannot be certain if cardiac sparing was actively used in
these trials. We await randomized evidence for the effec-
tiveness of cardiac-sparing techniques such as voluntary
breath holding to assess whether it reduces cardiac damage.
There have been 2 published meta-analyses of trials of
PBI (15, 16). However, we have addressed an important
outcome that was not addressed in these publications.
Lehman et al (15) used only the 3 older studies to evaluate
overall and cause-specific survival and did not evaluate
nonebreast cancer deaths. Marta et al (16) included only 2
of the older trials in their analysis of overall survival and 4
trials in their analysis of breast cancer survival and did not
evaluate nonebreast cancer mortality. The results of both
trials about breast cancer mortality are similar to our re-
sults. However, our study carefully evaluated nonebreast
cancer mortality and included all trials for which the data
were available, and it found a small yet statistically and
clinically significant difference between PBI and WBI fa-
voring PBI.in mortality between partial-breast irradiation (PBI) and
om-effects model. The trials included for nonebreast cancer
ELIOT (6), IMRT (7), and GEC-ESTRO (8). The median
initial 1222 patients in the TARGIT-A trial, whose median
ot included in the analysis of breast cancer (BC) deaths or
d, the random-effects model is more likely to reflect reality.
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analysis, we could not obtain the actual number of events in
the Christie Hospital trial, whose last report was published
23 years ago. Importantly, the overall mortality in two of
the excluded trials was very high and breast cancer mor-
tality was 20% to 30% (9, 10), as compared with <2% in
the included trials. This low breast cancer mortality seems
to be one of the reasons for the nonebreast cancer death
difference becoming evident in modern trials, and such a
difference may not have been detectable when breast cancer
mortality was high as in these older trials anyway. Finally,
overall survival in the Budapest trial was higher in the
partialbreast radiation therapy arm than in the wholebreast
radiation therapy arm (94.6% for PBI vs 91.8% for WBI).
We could not include these figures because the absolute
numbers of events for overall survival and breast cancer
survival were not available. If these events had been
included, it would have strengthened the results rather than
diluting them.
When the results of the Canadian RAPID, NSABP-B-39,
and IMPORT-LOW trials are available, we plan to combine
their data with longer-term results of the trials already
included to assess how they affect these meta-analysis
findings in the near future.
It would have been useful to assess whether there was
any difference between left- and right-sided cancers, but
these data were not available. However, the ratio of cardiac
risk for left-sided cancers to right-sided cancers is only 1.34
(17). With modern radiation therapy designed to reduce
cardiac dose, the absolute difference between sides is likely
to be even lower and undetectable with few events. In fact,
the finding of an overall reduction in nonebreast cancer
and total mortality suggests that such reduction may even
be larger in patients with left-sided breast cancers.
Individual patient data were not available for this anal-
ysis. However, the absolute numbers of events for each
randomized armdat a similar time pointdwere available
and can be used to answer the main question: How many
patients died at a median follow-up of 5 years? It should be
noted that for the TARGIT-A trial, data from only the initial
1222 patients whose median follow-up was 5 years have
been used for this meta-analysis.
Previous literature has suggested other-cause mortality
after WBI only appears many years after irradiation.
However, the 5-year breast cancer mortality in early trials is
up to 60%; thus it is likely that a small 1% to 2% difference
in early nonebreast cancer mortality would be masked. In
the modern era of very low breast cancer death rates, we
may be unmasking this true effect. Furthermore, several
studies have recently shown that sensitive instruments can
detect cardiac effects of radiation therapy within days (18);
within months (19); and as shown in a large Oxford over-
view, certainly within the first 5 years (17).
This meta-analysis has used modern data to address this
long-standing issue. It suggests that PBI does appear to
avoid deaths from other causes. The need to avoid even
very small harmful effects of treatment is vital todaybecause the overall survival and survival of patients with
T1N0 breast cancer are now nearly identical to women
without breast cancer (20).
When WBI is being discussed as part of breast-
conserving therapy, the option of using partial-breast radi-
ation therapy, along with the data showing the small yet
significant reduction in nonebreast cancer mortality,
should be discussed with appropriate patients before sur-
gery is performed.
We would like to conclude with two statements
regarding which there should be no controversy: (1) use of
PBI does not compromise breast cancer or overall mortal-
ity; and (2) the possibility that use of PBI instead of WBI
may reduce overall mortality can no longer be ignored or
ridiculeddit must be taken seriously. We remain cautious
and, given the long time-frame for outcomes in this
favorable population, seek longer follow-up of all the
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